{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:53:47Z","timestamp":1782849227430,"version":"3.54.5"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06746"],"award-info":[{"award-number":["23K06746"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-026-04202-5","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:38:27Z","timestamp":1776062307000},"page":"48-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era"],"prefix":"10.1007","volume":"124","author":[{"given":"Kentaro","family":"Ido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"4202_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann Intern Med. 2020;172:229\u201339.","journal-title":"Ann Intern Med"},{"issue":"Supplement 2","key":"4202_CR2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-019-0597-y","volume":"54","author":"A Pierini","year":"2019","unstructured":"Pierini A, Ruggeri L, Mancusi A, Carotti A, Falzetti F, Terenzi A, et al. T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease. Bone Marrow Transplant. 2019;54(Supplement 2):775\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"4202_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101035","volume":"62","author":"ZL Xu","year":"2023","unstructured":"Xu ZL, Huang XJ. Haploidentical transplants with a G-CSF\/ATG-based protocol: experience from China. Blood Rev. 2023;62:101035.","journal-title":"Blood Rev"},{"key":"4202_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153551","volume":"6","author":"T Inoue","year":"2021","unstructured":"Inoue T, Koyama M, Kaida K, Ikegame K, Ensbey KS, Samson L, et al. Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT. JCI Insight. 2021;6:e153551.","journal-title":"JCI Insight"},{"key":"4202_CR5","first-page":"273.e1","volume":"29","author":"K Kaida","year":"2023","unstructured":"Kaida K, Ikegame K, Inoue T, Maruyama S, Ishii S, Uchida N, et al. Peritransplantation glucocorticoid haploidentical stem cell transplantation is a promising strategy for AML patients with high leukemic burden: comparison with transplantations using other donor types. Transpl Cell Ther. 2023;29:273.e1-273.e9.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/ejh.13204","volume":"102","author":"S Kako","year":"2019","unstructured":"Kako S, Gomyo A, Akahoshi Y, Harada N, Kameda K, Ugai T, et al. Haploidentical transplantation using low-dose alemtuzumab: comparison with haploidentical transplantation using low-dose thymoglobulin. Eur J Haematol. 2019;102:256\u201364.","journal-title":"Eur J Haematol"},{"key":"4202_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","volume":"8","author":"PV O'Donnell","year":"2002","unstructured":"O\u2019Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2002;8:377\u201386.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41409-018-0279-1","volume":"54","author":"J Sugita","year":"2019","unstructured":"Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transpl. 2019;54:432\u201341.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR10","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","volume":"21","author":"J Sugita","year":"2015","unstructured":"Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant Cyclophosphamide after Busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transpl. 2015;21:1646\u201352.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2003-02-0430","volume":"102","author":"Y Kanda","year":"2003","unstructured":"Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991\u20132000). Blood. 2003;102:1541\u20137.","journal-title":"Blood"},{"key":"4202_CR12","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2011-08-372573","volume":"119","author":"J Kanda","year":"2012","unstructured":"Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, et al. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8\/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood. 2012;119:2409\u201316.","journal-title":"Blood"},{"key":"4202_CR13","doi-asserted-by":"publisher","first-page":"963689720976567","DOI":"10.1177\/0963689720976567","volume":"29","author":"J Kanda","year":"2020","unstructured":"Kanda J, Ando T, Kimura SI, Fujiwara SI, Imada K, Fujisawa S, et al. Hematopoietic stem cell transplantation from a related donor with human leukocyte antigen 1-antigen mismatch in the graft-versus-host direction using low-dose anti-thymocyte globulin. Cell Transpl. 2020;29:963689720976567.","journal-title":"Cell Transpl"},{"key":"4202_CR14","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1182\/bloodadvances.2020003110","volume":"4","author":"SR Solomon","year":"2020","unstructured":"Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, et al. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020;4:5311\u201321.","journal-title":"Blood Adv"},{"key":"4202_CR15","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/bjh.19630","volume":"205","author":"K Ido","year":"2024","unstructured":"Ido K, Nakamae H, Hattori N, Kanaya M, Morita K, Hino M, et al. Effect of peptide-binding motif on survival of HLA-haploidentical transplantation with post-transplant cyclophosphamide. Br J Haematol. 2024;205:1077\u201396.","journal-title":"Br J Haematol"},{"key":"4202_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","volume":"16","author":"YL Kasamon","year":"2010","unstructured":"Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transpl. 2010;16:482\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR17","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/bloodadvances.2023012133","volume":"8","author":"J Sanz","year":"2024","unstructured":"Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332\u201341.","journal-title":"Blood Adv"},{"key":"4202_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27126","volume":"99","author":"RM Saliba","year":"2024","unstructured":"Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, et al. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2024;99:38\u201347.","journal-title":"Am J Hematol"},{"key":"4202_CR19","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1007\/s00277-024-05848-z","volume":"103","author":"P Zieli\u0144ska","year":"2024","unstructured":"Zieli\u0144ska P, Wieczorkiewicz-Kabut A, Bia\u0142as K, Kocl\u0119ga A, Gruenpeter K, Kopi\u0144ska A, et al. Donor\u2019s age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide\u2014a single center experience. Ann Hematol. 2024;103:3095\u2013104.","journal-title":"Ann Hematol"},{"key":"4202_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000920","volume":"7","author":"MA Kharfan-Dabaja","year":"2023","unstructured":"Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, et al. Significance of degree of HLA disparity using T-cell replete peripheral blood stem cells from haploidentical donors with posttransplantation cyclophosphamide in AML in first complete hematologic remission: a study of the acute leukemia working party of the EBMT. Hemasphere. 2023;7:e920.","journal-title":"Hemasphere"},{"key":"4202_CR21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41409-023-01984-8","volume":"58","author":"A Pruitt","year":"2023","unstructured":"Pruitt A, Gao F, De Togni E, Cochran H, Godbole S, Slade M, et al. Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2023;58:855\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood.2021013443","volume":"139","author":"EJ Fuchs","year":"2022","unstructured":"Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MM, Modi D, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022;139:1452\u201368.","journal-title":"Blood"},{"key":"4202_CR23","doi-asserted-by":"publisher","first-page":"601.e1","DOI":"10.1016\/j.jtct.2022.06.023","volume":"28","author":"SR Solomon","year":"2022","unstructured":"Solomon SR, Aubrey MT, Zhang X, Jackson KC, Roark CL, Freed BM, et al. Lineage-specific relapse prediction after haploidentical transplantation with post-transplant cyclophosphamide based on recipient HLA-B-leader genotype and HLA-C-group KIR ligand. Transplant Cell Ther. 2022;28:601.e1-601.e8.","journal-title":"Transplant Cell Ther"},{"key":"4202_CR24","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","volume":"5","author":"AE DeZern","year":"2021","unstructured":"DeZern AE, Franklin C, Tsai HL, Imus PH, Cooke KR, Varadhan R, et al. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021;5:1360\u20138.","journal-title":"Blood Adv"},{"key":"4202_CR25","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/bloodadvances.2020001620","volume":"4","author":"J Mariotti","year":"2020","unstructured":"Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4:3900\u201312.","journal-title":"Blood Adv"},{"key":"4202_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","volume":"2","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018;2:299\u2013307.","journal-title":"Blood Adv"},{"key":"4202_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/ajh.24963","volume":"93","author":"J Canaani","year":"2018","unstructured":"Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93:246\u201353.","journal-title":"Am J Hematol"},{"key":"4202_CR28","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","volume":"24","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transpl. 2018;24:1232\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.clml.2024.05.011","volume":"24","author":"RS Mehta","year":"2024","unstructured":"Mehta RS. SOHO state of the art updates and next questions | Current status and future directions of donor selection. Clin Lymphoma Myeloma Leuk. 2024;24:821\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4202_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","volume":"55","author":"SO Ciurea","year":"2020","unstructured":"Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:12\u201324.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR31","unstructured":"CIBMTR. A predictor for probability of disease-free survival after haploidentical transplant. https:\/\/haplodonorselector.b12x.org\/."},{"key":"4202_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2018;53:521\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/bmt.2011.131","volume":"47","author":"S Yoshihara","year":"2012","unstructured":"Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transpl. 2012;47:508\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR34","first-page":"538.e1","volume":"30","author":"P Chor\u00e3o","year":"2024","unstructured":"Chor\u00e3o P, Henriques M, Villalba M, Montoro J, Balaguer-Rosello A, Gonzalez EM, et al. Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide. Transpl Cell Ther. 2024;30:538.e1-538.e10.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR35","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","volume":"5","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1739\u201348.","journal-title":"JAMA Oncol"},{"key":"4202_CR36","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/bloodadvances.2019000614","volume":"3","author":"MA Meybodi","year":"2019","unstructured":"Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019;3:2581\u20135.","journal-title":"Blood Adv"},{"key":"4202_CR37","first-page":"973","volume":"31","author":"AM Jimenez Jimenez","year":"2025","unstructured":"Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, et al. Allogeneic hematopoietic cell donor selection: contemporary guidelines from the NMDP\/CIBMTR. Transpl Cell Ther. 2025;31:973\u201388.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR38","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1007\/s00277-024-05944-0","volume":"103","author":"J Sugita","year":"2024","unstructured":"Sugita J, Morita K, Konuma T, Yanada M. Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia. Ann Hematol. 2024;103:4851\u201368.","journal-title":"Ann Hematol"},{"key":"4202_CR39","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41409-022-01822-3","volume":"57","author":"Y Atsuta","year":"2022","unstructured":"Atsuta Y, Sugita J, Nakamae H, Maruyama Y, Ishiyama K, Shiratori S, et al. Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation. Bone Marrow Transpl. 2022;57:1781\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR40","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","volume":"5","author":"MR Grunwald","year":"2021","unstructured":"Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, et al. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021;5:975\u201383.","journal-title":"Blood Adv"},{"key":"4202_CR41","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6:920\u201330.","journal-title":"Blood Adv"},{"key":"4202_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","volume":"3","author":"P Dreger","year":"2019","unstructured":"Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3:360\u20139.","journal-title":"Blood Adv"},{"key":"4202_CR43","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/bjh.19825","volume":"205","author":"M Moriguchi","year":"2024","unstructured":"Moriguchi M, Nakamae H, Nishimoto M, Sugita J, Yanada M, Toubai T, et al. Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia. Br J Haematol. 2024;205:2376\u201386.","journal-title":"Br J Haematol"},{"key":"4202_CR44","first-page":"316.e1","volume":"30","author":"Y Nakaya","year":"2024","unstructured":"Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide versus HLA-matched unrelated donor transplantation for myelodysplastic syndrome. Transpl Cell Ther. 2024;30:316.e1-316.e12.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR45","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487\u201396.","journal-title":"N Engl J Med"},{"key":"4202_CR46","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/s41409-021-01314-w","volume":"56","author":"S Shiratori","year":"2021","unstructured":"Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y, et al. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transpl. 2021;56:2231\u201340.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR47","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1097\/TP.0000000000000976","volume":"100","author":"A Ravinet","year":"2016","unstructured":"Ravinet A, Cabrespine A, Soci\u00e9 G, Milpied N, Yakoub Agha I, Nguyen S, et al. Impact of thymoglobulin by stem cell source (peripheral blood stem cell or bone marrow) after myeloablative stem cell transplantation from HLA 10\/10-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Transplantation. 2016;100:1732\u20139.","journal-title":"Transplantation"},{"key":"4202_CR48","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s12185-019-02631-z","volume":"109","author":"S Fuji","year":"2019","unstructured":"Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, et al. Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT. Int J Hematol. 2019;109:684\u201393.","journal-title":"Int J Hematol"},{"key":"4202_CR49","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1182\/bloodadvances.2024013719","volume":"8","author":"A Arslan","year":"2024","unstructured":"Arslan A, Labuhn S, Sala E, Ringhoffer M, Schetelig J, Schr\u00f6der T, et al. Outcomes of haploidentical transplants with PT-CY vs 10\/10 MUD transplants with ATG in Germany. Blood Adv. 2024;8:6104\u201313.","journal-title":"Blood Adv"},{"key":"4202_CR50","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41409-023-02042-z","volume":"58","author":"MJ Rieger","year":"2023","unstructured":"Rieger MJ, Stolz SM, M\u00fcller AM, Schwotzer R, Nair G, Schneidawind D, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm. Bone Marrow Transpl. 2023;58:1121\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR51","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"13","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46.","journal-title":"J Hematol Oncol"},{"key":"4202_CR52","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","volume":"14","author":"J Sanz","year":"2021","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Sergeevich MI, Angelucci E, et al. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. J Hematol Oncol. 2021;14:84.","journal-title":"J Hematol Oncol"},{"key":"4202_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273\u201382.","journal-title":"Blood"},{"key":"4202_CR54","first-page":"377.e1","volume":"29","author":"RS Mehta","year":"2023","unstructured":"Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE, et al. Impact of Donor age in haploidentical-post-transplantation cyclophosphamide versus matched unrelated donor post-transplantation cyclophosphamide hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Transpl Cell Ther. 2023;29:377.e1-377.e7.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR55","first-page":"184.e1","volume":"29","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Finel H Sr, et al. Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas. Transpl Cell Ther. 2023;29:184.e1-184.e9.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR56","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","volume":"6","author":"AEC Broers","year":"2022","unstructured":"Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk KM, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378\u201385.","journal-title":"Blood Adv"},{"key":"4202_CR57","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"4202_CR58","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.bbmt.2015.12.027","volume":"22","author":"J Kanda","year":"2016","unstructured":"Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, et al. Graft-versus-host disease after HLA-matched sibling bone marrow or peripheral blood stem cell transplantation: comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Transpl. 2016;22:744\u201351.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02130","author":"AH Kelkar","year":"2026","unstructured":"Kelkar AH, Abel GA, Cutler CS, Lee SJ, Soiffer RJ. Is it time to move beyond graft-versus-host disease-free, relapse-free survival as a primary end point in clinical trials for hematopoietic cell transplantation? J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO-25-02130.","journal-title":"J Clin Oncol"},{"key":"4202_CR60","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","volume":"23","author":"Stem Cell Trialists' Collaborative Group","year":"2005","unstructured":"Stem Cell Trialists\u2019 Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074\u201387.","journal-title":"J Clin Oncol"},{"key":"4202_CR61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med"},{"key":"4202_CR62","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3324\/haematol.2016.149427","volume":"101","author":"Y Inamoto","year":"2016","unstructured":"Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016;101:1592\u2013602.","journal-title":"Haematologica"},{"key":"4202_CR63","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157\u201367.","journal-title":"Lancet Haematol"},{"key":"4202_CR64","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.bbmt.2016.01.012","volume":"22","author":"R Kumar","year":"2016","unstructured":"Kumar R, Kimura F, Ahn KW, Hu Z-H, Kuwatsuka Y, Klein JP, et al. Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions. Biol Blood Marrow Transpl. 2016;22:932\u201340.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"G Battipaglia","year":"2021","unstructured":"Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:209\u201318.","journal-title":"Cancer"},{"key":"4202_CR66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","volume":"13","author":"E Brissot","year":"2020","unstructured":"Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:87.","journal-title":"J Hematol Oncol"},{"key":"4202_CR67","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1002\/cncr.35004","volume":"129","author":"S Giebel","year":"2023","unstructured":"Giebel S, Labopin M, Salmenniemi U, Soci\u00e9 G, Bondarenko S, Blaise D, et al. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2023;129:3735\u201345.","journal-title":"Cancer"},{"key":"4202_CR68","doi-asserted-by":"publisher","first-page":"695.e1","DOI":"10.1016\/j.jtct.2022.07.021","volume":"28","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, et al. Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation. Transplant Cell Ther. 2022;28:695.e1-695.e10.","journal-title":"Transplant Cell Ther"},{"key":"4202_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"E Brissot","year":"2024","unstructured":"Brissot E, Labopin M, Labussiere H, Fossard G, Chevallier P, Guillaume T, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 2024;14:31.","journal-title":"Blood Cancer J"},{"key":"4202_CR70","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.24.00184","volume":"42","author":"BC Shaffer","year":"2024","unstructured":"Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bola\u00f1os-Meade J, Abboud R, et al. Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors. J Clin Oncol. 2024;42:3277\u201386.","journal-title":"J Clin Oncol"},{"key":"4202_CR71","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1182\/bloodadvances.2024013468","volume":"8","author":"Y Chalandon","year":"2024","unstructured":"Chalandon Y, Eikema DJ, Moiseev I, Ciceri F, Koster L, Vydra J, et al. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms. Blood Adv. 2024;8:4792\u2013802.","journal-title":"Blood Adv"},{"key":"4202_CR72","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2014-10-604785","volume":"125","author":"Y Morishima","year":"2015","unstructured":"Morishima Y, Kashiwase K, Matsuo K, Azuma F, Morishima S, Onizuka M, et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood. 2015;125:1189\u201397.","journal-title":"Blood"},{"key":"4202_CR73","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbmt.2019.07.028","volume":"25","author":"LJ Arcuri","year":"2019","unstructured":"Arcuri LJ, Aguiar MTM, Ribeiro AAF, Pacheco AGF. Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25:2422\u201330.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4202_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2018025643","volume":"3","author":"M Wakamatsu","year":"2019","unstructured":"Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, et al. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. Blood Adv. 2019;3:105\u201315.","journal-title":"Blood Adv"},{"key":"4202_CR75","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3324\/haematol.2017.187450","volume":"104","author":"E Brissot","year":"2019","unstructured":"Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica. 2019;104:524\u201332.","journal-title":"Haematologica"},{"key":"4202_CR76","first-page":"909.e1","volume":"30","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Petersdorf EW, Wang T, Lee SJ. Haploidentical versus mismatched unrelated donor hematopoietic cell transplantation: HLA factors and donor age considerations. Transpl Cell Ther. 2024;30:909.e1-909.e11.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR77","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","volume":"6","author":"MJ Wieduwilt","year":"2022","unstructured":"Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022;6:339\u201357.","journal-title":"Blood Adv"},{"key":"4202_CR78","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41409-022-01781-9","volume":"57","author":"F Baron","year":"2022","unstructured":"Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, et al. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia. Bone Marrow Transpl. 2022;57:1657\u201363.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR79","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1002\/cncr.34452","volume":"128","author":"A Nagler","year":"2022","unstructured":"Nagler A, Labopin M, Arat M, Rem\u00e9nyi P, Koc Y, Blaise D, et al. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT. Cancer. 2022;128:3959\u201368.","journal-title":"Cancer"},{"key":"4202_CR80","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41409-024-02400-5","volume":"59","author":"A Nagler","year":"2024","unstructured":"Nagler A, Labopin M, Swoboda R, Blaise D, Angelucci E, Vydra J, et al. Young (<35 years) haploidentical versus old (\u226535 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2024;59:1552\u201362.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR81","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41409-022-01577-x","volume":"57","author":"G Battipaglia","year":"2022","unstructured":"Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, et al. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2022;57:562\u201371.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR82","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","volume":"14","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, G\u00fclbas Z, Gedde-Dahl T, et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 2024;14:45.","journal-title":"Blood Cancer J"},{"key":"4202_CR83","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41409-024-02225-2","volume":"59","author":"A Paviglianiti","year":"2024","unstructured":"Paviglianiti A, Ngoya M, Pe\u00f1a M, Boumendil A, G\u00fclbas Z, Ciceri F, et al. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transpl. 2024;59:597\u2013603.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR84","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/bmt.2015.265","volume":"51","author":"S Fuji","year":"2016","unstructured":"Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma. Bone Marrow Transpl. 2016;51:205\u201311.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR85","unstructured":"Japan Marrow Donor Program. Annual Report 2024."},{"key":"4202_CR86","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12185-018-2413-7","volume":"107","author":"N Kawashima","year":"2018","unstructured":"Kawashima N, Nishiwaki S, Shimizu N, Kamoshita S, Watakabe K, Yokohata E, et al. Outcomes of strategic alternative donor selection or suspending donor search based on Japan Marrow Donor Program coordination status. Int J Hematol. 2018;107:551\u20138.","journal-title":"Int J Hematol"},{"key":"4202_CR87","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2019.10.014","volume":"26","author":"J Sanz","year":"2020","unstructured":"Sanz J, Montoro J, Solano C, Valc\u00e1rcel D, Sampol A, Ferr\u00e1 C, et al. Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transpl. 2020;26:358\u201366.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4202_CR88","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood.2020007535","volume":"137","author":"EJ Fuchs","year":"2021","unstructured":"Fuchs EJ, O\u2019Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137:420\u20138.","journal-title":"Blood"},{"key":"4202_CR89","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41409-022-01770-y","volume":"57","author":"J Sugita","year":"2022","unstructured":"Sugita J, Atsuta Y, Nakamae H, Maruyama Y, Ishiyama K, Shiratori S, et al. Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation. Bone Marrow Transpl. 2022;57:1681\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR90","first-page":"365.e1","volume":"29","author":"T Konuma","year":"2023","unstructured":"Konuma T, Matsuda K, Shimomura Y, Tanoue S, Sugita J, Inamoto Y, et al. Effect of graft-versus-host disease on post-transplantation outcomes following single cord blood transplantation compared with haploidentical transplantation with post-transplantation cyclophosphamide for adult acute myeloid leukemia. Transpl Cell Ther. 2023;29:365.e1-365.e11.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR91","first-page":"766.e1","volume":"29","author":"Y Onishi","year":"2023","unstructured":"Onishi Y, Mori T, Yamazaki H, Hiramoto N, Zaimoku Y, Kanaya M, et al. Comparison of haploidentical stem cell transplantation with post-transplantation cyclophosphamide versus umbilical cord blood transplantation in adult patients with aplastic anemia. Transpl Cell Ther. 2023;29:766.e1-766.e8.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR92","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/bjh.19372","volume":"204","author":"T Jo","year":"2024","unstructured":"Jo T, Ueda T, Akahoshi Y, Kondo T, Uchida N, Tanaka M, et al. First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia. Br J Haematol. 2024;204:1913\u20139.","journal-title":"Br J Haematol"},{"key":"4202_CR93","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41409-024-02423-y","volume":"59","author":"M Nishikubo","year":"2024","unstructured":"Nishikubo M, Shimomura Y, Nakaya Y, Shinohara A, Uchida N, Takayama N, et al. Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed\/refractory non-Hodgkin lymphoma. Bone Marrow Transpl. 2024;59:1735\u201343.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR94","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/bjh.19835","volume":"206","author":"M Yoshimitsu","year":"2025","unstructured":"Yoshimitsu M, Tanaka T, Nakano N, Kato K, Muranushi H, Tokunaga M, et al. Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia\/lymphoma. Br J Haematol. 2025;206:235\u201349.","journal-title":"Br J Haematol"},{"key":"4202_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02729-5","author":"M Yanada","year":"2025","unstructured":"Yanada M, Yamasaki S, Mizuno S, Sugita J, Fujino T, Misaki Y, et al. Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia. Bone Marrow Transpl. 2025. https:\/\/doi.org\/10.1038\/s41409-025-02729-5.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR96","first-page":"710.e1","volume":"28","author":"A Ruggeri","year":"2022","unstructured":"Ruggeri A, Galimard JE, Labopin M, Rafii H, Blaise D, Ciceri F, et al. Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myelogenous leukemia: a study on behalf of Eurocord and the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Transpl Cell Ther. 2022;28:710.e1-710.e10.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR97","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/bloodadvances.2024014938","volume":"9","author":"T Nagayama","year":"2025","unstructured":"Nagayama T, Fujiwara SI, Nishiwaki S, Wada F, Uchida N, Tanaka M, et al. Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation. Blood Adv. 2025;9:3226\u201337.","journal-title":"Blood Adv"},{"key":"4202_CR98","first-page":"103.e1","volume":"31","author":"K Harada","year":"2025","unstructured":"Harada K, Kanda J, Hirayama M, Wada F, Uchida N, Tanaka M, et al. Comparison of nonrelapse mortality after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide versus single umbilical cord blood transplantation in hematologic disease. Transpl Cell Ther. 2025;31:103.e1-103.e13.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR99","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/bloodadvances.2021004462","volume":"5","author":"JE Wagner","year":"2021","unstructured":"Wagner JE, Ballen KK, Zhang MJ, Allbee-Johnson M, Karanes C, Milano F, et al. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv. 2021;5:4064\u201372.","journal-title":"Blood Adv"},{"key":"4202_CR100","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/ejh.12723","volume":"97","author":"M Yanada","year":"2016","unstructured":"Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K, et al. Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. Eur J Haematol. 2016;97:278\u201387.","journal-title":"Eur J Haematol"},{"key":"4202_CR101","first-page":"161.e1","volume":"28","author":"S Kako","year":"2022","unstructured":"Kako S, Hayakawa F, Miyamura K, Tanaka J, Imai K, Kanda J, et al. Decision analysis for unrelated bone marrow transplantation or immediate cord blood transplantation for patients with philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Transpl Cell Ther. 2022;28:161.e1-161.e10.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR102","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41409-020-0859-8","volume":"55","author":"S Terakura","year":"2020","unstructured":"Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, et al. Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. Bone Marrow Transpl. 2020;55:1399\u2013409.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR103","first-page":"622","volume":"29","author":"Y Morishima","year":"2023","unstructured":"Morishima Y, Watanabe-Okochi N, Kai S, Azuma F, Kimura T, Matsumoto K, et al. Selection of cord blood unit by CD34(+) cell and GM-CFU numbers and allele-level HLA matching in single cord blood transplantation. Transpl Cell Ther. 2023;29:622\u201331.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR104","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/bmt.2012.172","volume":"48","author":"S Kurosawa","year":"2013","unstructured":"Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia\/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Bone Marrow Transpl. 2013;48:529\u201336.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR105","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/bjh.70099","volume":"207","author":"T Konuma","year":"2025","unstructured":"Konuma T, Kanda J, Uchida N, Tanaka M, Kimura F, Nakasone H, et al. Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan. Br J Haematol. 2025;207:2026\u201340.","journal-title":"Br J Haematol"},{"key":"4202_CR106","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-021-01086-2","volume":"14","author":"B Dholaria","year":"2021","unstructured":"Dholaria B, Labopin M, Sanz J, Ruggeri A, Cornelissen J, Labussi\u00e8re-Wallet H, et al. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. J Hematol Oncol. 2021;14:76.","journal-title":"J Hematol Oncol"},{"key":"4202_CR107","first-page":"1005.e1","volume":"27","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Yamasaki S, Harada K, Iwasaki M, Kobayashi A, et al. Allogeneic hematopoietic cell transplantation from alternative donors in acute myelogenous leukemia: a comparative analysis. Transpl Cell Ther. 2021;27:1005.e1-1005.e8.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR108","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1038\/s41409-021-01387-7","volume":"56","author":"F Baron","year":"2021","unstructured":"Baron F, Ngoya M, Labopin M, Cornelissen JJ, Ganser A, Forcade E, et al. Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transpl. 2021;56:2742\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"4202_CR109","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41375-024-02497-z","volume":"39","author":"C Orvain","year":"2025","unstructured":"Orvain C, Milano F, Rodr\u00edguez-Arbol\u00ed E, Othus M, Petersdorf EW, Sandmaier BM, et al. Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia. Leukemia. 2025;39:381\u201390.","journal-title":"Leukemia"},{"key":"4202_CR110","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1602074","volume":"375","author":"F Milano","year":"2016","unstructured":"Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944\u201353.","journal-title":"N Engl J Med"},{"key":"4202_CR111","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-019-0204-x","volume":"9","author":"F Baron","year":"2019","unstructured":"Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, et al. Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. Blood Cancer J. 2019;9:46.","journal-title":"Blood Cancer J"},{"key":"4202_CR112","first-page":"215.e1","volume":"30","author":"T Konuma","year":"2024","unstructured":"Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, et al. Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8\/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free survival compared with matched sibling donors during nonremission status. Transpl Cell Ther. 2024;30:215.e1-215.e18.","journal-title":"Transpl Cell Ther"},{"key":"4202_CR113","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1158\/1078-0432.CCR-20-4856","volume":"27","author":"T Konuma","year":"2021","unstructured":"Konuma T, Kanda J, Kuwatsuka Y, Yanada M, Kondo T, Hirabayashi S, et al. Differential effect of graft-versus-host disease on survival in acute leukemia according to donor type. Clin Cancer Res. 2021;27:4825\u201335.","journal-title":"Clin Cancer Res"},{"key":"4202_CR114","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Labopin M, Kr\u00f6ger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892\u20139.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04202-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04202-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04202-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:14:19Z","timestamp":1782846859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04202-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04202-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article, as no datasets were generated or analyzed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}